Search Results - "Lippincott, Isabel"

Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations by Gomez, Eliana B., Isabel, Lippincott, Rosendahal, Mary S., Rothenberg, Stephen M., Andrews, Steven W., Brandhuber, Barb J.

“…Introduction: Bruton's Tyrosine Kinase (BTK) is an essential component of normal and malignant B-cell receptor signaling. Covalent BTK inhibitors have…”
Get full text

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor by Gomez, Eliana B., Ebata, Kevin, Randeria, Hetal S., Rosendahl, Mary S., Cedervall, E. Peder, Morales, Tony H., Hanson, Lauren M., Brown, Nicholas E., Gong, Xueqian, Stephens, Jennifer, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A., Abada, Paolo B., Ballard, Joshua A., Allerston, Charles K., Brandhuber, Barbara J.

“…•Pirtobrutinib is a potent, noncovalent (reversible), highly selective inhibitor of BTK and C481-mutant BTK.•Pirtobrutinib is efficacious in B-cell models…”
Get full text

Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor by Gomez, Eliana B, Ebata, Kevin, Randeria, Hetal S, Rosendahl, Mary S, Cedervall, Ernst Peder, Morales, Tony H, Hanson, Lauren M, Brown, Nicholas E, Gong, Xueqian, Stephens, Jennifer Rachelle, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A, Abada, Paolo B, Ballard, Joshua A, Allerston, Charles K, Brandhuber, Barbara J

“…Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell driven malignancies. However, approved covalent BTK…”
Get full text